Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-24
DOI
10.1038/s41598-018-34293-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria
- (2017) Leo Richter et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary
- (2017) Lilla Pogácsás et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug survival of biologic treatments in psoriasis: a systematic review
- (2017) Daniel J. No et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug survival in psoriatic patients treated with biologic agent for the first time
- (2017) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Biologic drug survival in Israeli psoriasis patients
- (2017) Guy Shalom et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of Uveitis Among People With Psoriasis
- (2017) Ching-Chi Chi et al. JAMA Ophthalmology
- Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria
- (2016) M Inzinger et al. ACTA DERMATO-VENEREOLOGICA
- Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study
- (2016) Joseph EC Marinas et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t
- (2016) J. Zweegers et al. BRITISH JOURNAL OF DERMATOLOGY
- Drug survival rates and reasons for drug discontinuation in psoriasis
- (2016) Tobias Arnold et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice
- (2016) Eva Vilarrasa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment
- (2016) Juul M.P.A. van den Reek et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population
- (2016) Jalpa A. Doshi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- (2016) A. Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective
- (2015) Christopher Ross et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis
- (2015) Arnd Jacobi et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Healing Refractory Venous Ulcers: New Treatments Offer Hope
- (2015) Robert S. Kirsner et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2015) Richard B. Warren et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results
- (2015) Alexa B. Kimball et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- British Society for Cutaneous Allergy
- (2014) BRITISH JOURNAL OF DERMATOLOGY
- ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
- (2014) J.M.P.A. van den Reek et al. BRITISH JOURNAL OF DERMATOLOGY
- Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis
- (2014) S.P. Menting et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
- (2014) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system
- (2014) Shu-Hui Wang et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry
- (2014) J.M.P.A. van den Reek et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Drug Survival Rates And Cost of Biological Agents for the Treatment of Moderate to Severe Psoriasis in the Balearic Islands (Spain)
- (2014) P. Ventayol VALUE IN HEALTH
- Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle
- (2014) Ching-Chi Chi et al. Biomed Research International
- Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study
- (2013) M. Esposito et al. BRITISH JOURNAL OF DERMATOLOGY
- Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre
- (2013) A. López-Ferrer et al. BRITISH JOURNAL OF DERMATOLOGY
- Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis
- (2013) J.M.P.A. van den Reek et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
- (2013) Machaon Bonafede et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug survival rates in patients with psoriasis after treatment with biologics
- (2013) Yoshinori Umezawa et al. JOURNAL OF DERMATOLOGY
- Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions
- (2013) J. Spertino et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Drug survival rates of biologic treatments in patients with psoriasis vulgaris
- (2011) A.M.G. Brunasso et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
- (2011) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
- (2011) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- A Novel Composite Endpoint to Evaluate the Gastrointestinal (GI) Effects of Nonsteroidal Antiinflammatory Drugs Through the Entire GI Tract
- (2009) F. K. L. CHAN et al. JOURNAL OF RHEUMATOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started